Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1

4 Jun 2007

Abstract excerpt

OBJECTIVES: BAY 57-1293 is a helicase-primase inhibitor (HPI) from a new class of antivirals that are highly efficacious in herpes simplex virus (HSV)-1 animal infection models. Resistant mutants with point mutations in the helicase (UL5) were reported to be present in laboratory isolates at a low frequency of approximately 10(-6). In contrast, we have shown elsewhere that some laboratory isolates contain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Poxvirus research and outbreaks
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17550887
DOI: 10.1093/jac/dkm182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1PMID 17550887Read ↗

Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.Semantic proximity Read ↗

Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitorSemantic proximity Read ↗

Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).Semantic proximity Read ↗

Herpes Simplex Virus Helicase—Primase Inhibitors: Recent Findings from the Study of Drug Resistance MutationsSemantic proximity Read ↗

A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs' Susceptibility.Semantic proximity Read ↗

High prevalence but low clinical impact of acyclovir-resistant herpes simplex virus type 1 infections in patients with hematologic disorders.Semantic proximity Read ↗

No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.Semantic proximity Read ↗

Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virusSemantic proximity Read ↗

Low frequency variants can predetermine antiviral drug resistance development in herpes simplex virus type 1.Semantic proximity Read ↗

Evaluating phenotype and genotype of drug-resistant strains in herpesviruses.Semantic proximity Read ↗

Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.Semantic proximity Read ↗

The DNA helicase–primase complex as a target for herpes viral infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.